Piratin

Quick links to important sections

Piratin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Piratin

Quick Facts

Property Description
Active ingredient Piracetam
Form Tablets, Capsules, Solution for Injection
Pharmacological class Nootropic / Psychoanaleptic
Common use Cognitive support and enhancement
Origin Synthetic

What Type of Medicine is Piratin?

Piratin is classified as a nootropic agent, whose active component is the synthetic substance Piracetam. This compound is recognized as the definitive prototype of the entire Racetam chemical class, a fact that differentiates it from subsequent analogues in its foundational pharmacological role. Piracetam is categorized under the pharmacological group of Psychoanaleptic agents (ATC code N06BX). It is a synthetic derivative, chemically related to gamma-aminobutyric acid (GABA), and is clinically recognized for its potential to modulate cognitive function without the direct sedative or stimulant effects associated with many traditional psychotropic medications.

In What Forms is Piratin Available?

Piratin is formulated as a single-ingredient product, containing only Piracetam as the active therapeutic component. Piracetam is available in various pharmaceutical presentations, including oral tablets and capsules, which allow for administration via the oral route. It is also supplied as sterile aqueous solutions for injection, which is specifically utilized to enable administration through intravenous or intramuscular routes. Its highly water-soluble nature supports these diverse preparations.

What is the Core Function of a Nootropic Like Piratin?

The core function of Piratin is to provide foundational support for cerebral function and cognitive processes, such as memory and attention. Pharmacological data indicates that Piracetam enhances the efficiency of neuronal communication and maintains the structural integrity of neuronal cell membranes, demonstrating a neuroprotective capacity. This stabilizing action is complemented by its ability to influence blood flow dynamics, notably by enhancing the deformability of red blood cells, a mechanism that contributes to improved microcirculation and nutrient supply within the brain. This role supports the maintenance of mental acuity.

What side effects are possible with Piratin?

Possible Side Effects and Safety Information

The officially documented adverse effects for Piratin are classified into frequency categories as per regulatory standards. These effects are primarily observed in the central nervous system, psychiatric, and gastrointestinal systems.

Category Officially Documented Reactions
Common (1/100, < 1/10) Nervousness, hyperkinesia, and weight increased.
Uncommon (1/1,000, < 1/100) Depression, somnolence (drowsiness), and asthenia (weakness).
Not Known Agitation, anxiety, confusion, headache, insomnia, diarrhea, nausea, vomiting, and various hypersensitivity reactions.

Safety Constraints and Special Considerations

The regulatory label strictly defines several safety constraints and conditions under which the medicine must not be used (contraindications):

  • Serious Contraindications: Piratin is formally contraindicated in patients with cerebral haemorrhage, those with end-stage renal disease (creatinine clearance less than 20 mL/min), and individuals with Huntington's Chorea.
  • Renal Function: Specific adjustments are required for patients with any degree of renal impairment, as the dose must be individualized based on the measured creatinine clearance to maintain safety. No dose adjustment is specified for isolated hepatic impairment.
  • Haemorrhagic Risk: Caution is specified for patients with haemorrhagic disorders or those undergoing major surgery due to the drug's documented effect on platelet aggregation.
  • Withdrawal Safety: The label notes that abrupt cessation should be avoided to prevent the possibility of sudden relapse or withdrawal seizures, particularly in patients being treated for myoclonus.

These official safety statements structure the understanding of Piratin's risk profile by detailing the likely adverse effects, enforcing absolute prohibitions against use in specific high-risk conditions, and mandating patient status checks related to kidney function.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on overdose for Piracetam is based on reported cases and defined supportive actions. The highest oral overdose reported was 75 grams in a single case.

Domain Official Regulatory Statement
Documented Manifestations Clinical signs observed in the reported high-dose case were bloody diarrhoea and abdominal pain.
Attribution These gastrointestinal signs were officially attributed as most probably related to the extreme high dose of sorbitol, an excipient in the used formulation.
Active Substance Toxicity No additional adverse events specifically related to overdose from the Piracetam active substance itself have been reported in official labeling.

Emergency Management

Overdose management is defined as symptomatic treatment and requires medical evaluation. No specific antidote is known for Piracetam overdose.

Regulator-described procedural steps in cases of acute, significant overdosage include measures to empty the stomach, such as gastric lavage or induction of emesis. The treatment may also include hemodialysis, with the official documentation noting that the extraction efficiency of the dialyser is 50 to 60% for the drug. There are no specific, separate overdose considerations detailed for populations such as the elderly or children in the official regulatory sections.

Therapeutic Uses of Piratin

Piratin's use is generally considered relevant across several neurological domains and is used for managing symptoms that interfere with daily functioning. The medication may assist with symptom clusters related to cognitive decline, vestibular disorders, and involuntary neurological movement.


What Piratin Treats: Main Uses and Benefits

A therapeutic use of Piratin involves supportive relief in conditions characterized by periods of heightened symptoms, such as the involuntary muscle jerks of cortical myoclonus, the discomfort associated with vertigo and chronic imbalance, and specific difficulties in memory, attention, and learning. The medication is commonly applied in addressing conditions like mild age-related cognitive impairment, recurrent vertigo, and specific reading difficulties in children (dyslexia). In these clinical scenarios, it is relevant when supportive symptom management is appropriate.

It contributes to easing the overall symptom load during symptomatic periods and assists with supporting functional stability.

Quick Fact: Symptom Support
Therapeutic Role Supports management of symptoms that interfere with daily functioning, including cognitive issues and balance disorders.
Symptom Focus Used for easing difficulties related to memory, concentration, chronic dizziness, and involuntary muscle jerks.
Application Relevant in clinical settings that involve recurrent or fluctuating symptom patterns like mild cognitive impairment and cortical myoclonus.

Eligibility and Restrictions for Use

Piratin eligibility is defined by official regulatory documentation and is strictly dependent on the patient's existing health status, particularly concerning renal function and certain neurological conditions.

Populations for Whom Use is Contraindicated

The medicine must not be used (is contraindicated) in patients with the following conditions, as stated in the label:

  • Severe Renal Impairment or End-Stage Renal Disease (creatinine clearance less than 20 mL/min or <30 mL/min).
  • Cerebral Hemorrhage.
  • Huntington’s Chorea.
  • Known Hypersensitivity to Piracetam or other pyrrolidone derivatives.

Condition-Specific and Age-Related Eligibility

Population Category Regulatory Eligibility Status
Pregnancy and Lactation Not Recommended. Use should be avoided or discontinued, as the drug crosses the placenta and is excreted in breast milk.
Risk of Bleeding Caution is Recommended. Includes patients with severe hemorrhage or a history of hemorrhagic cerebrovascular accident (CVA).
Older Adults Conditional Use. Regular evaluation of renal function (creatinine clearance) is required for long-term treatment.
Mild/Moderate Renal Impairment Conditional Use. Patients are eligible, but the daily dose must be reduced and individualized based on the level of impairment.
Children under 16 Not Recommended in certain regulatory jurisdictions.

Official labeling maintains that use is conditional upon these specific patient characteristics, ensuring that the medicine is excluded from high-risk groups as formally defined by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Piratin details specific pharmacodynamic and pharmacokinetic patterns that govern co-administration.

Pharmacodynamic Overlap The drug’s documented effect on platelet function leads to an additive effect on hemostasis when co-administered with anticoagulants or antiplatelet agents. This combination is formally noted to prolong bleeding time and decrease platelet aggregation. Furthermore, co-treatment with Thyroid Hormones (T3 and T4) has been associated with reported central nervous system effects, including confusion, irritability, and sleep disorder.

Metabolic and Clearance Profile Piratin exhibits a low potential for typical drug-drug interactions because approximately 90% is eliminated unchanged by the kidneys. Regulatory documents confirm no significant inhibition of major Cytochrome P450 enzyme isoforms and no modification of serum levels for co-administered antiepileptic medicines (e.g., Carbamazepine, Valproate). Co-use of alcohol has also been documented as having no pharmacokinetic effect.

However, the clearance profile creates a primary restriction: Severe renal impairment is a formal contraindication due to the risk of drug accumulation. Use is also restricted in conditions involving an existing bleeding risk, such as cerebral haemorrhage.

Mechanism of Action

Piratin (Piracetam) exerts its biological effects through a multi-faceted mechanism that modulates neuronal function, increases cellular resistance to stress, and alters microcirculatory properties.


Modulation of Neuronal and Erythrocyte Membranes

This domain defines the drug's fundamental action through direct interaction with the phospholipid bilayer of cell membranes, including those of neurons and red blood cells. By normalizing compromised membrane fluidity, this mechanism affects the function of membrane-bound structures, and the resulting change in red blood cell deformability alters cerebral microcirculation and metabolic delivery.


Positive Allosteric Modulation of AMPA Receptors

Piracetam selectively modulates excitatory synaptic signaling by binding to an allosteric site on the AMPA receptor, primarily affecting the glutamatergic system. This positive allosteric effect slows receptor desensitization, which facilitates the transmission of existing neural signals and influences the underlying physiological components associated with synaptic plasticity.


Influence on Cellular Bioenergetics

This mechanism increases the structural integrity and resistance of neuronal tissue by stabilizing the inner mitochondrial membrane potential, which is vital for sustained ATP synthesis. This action influences the cell's capacity to maintain activity during metabolic insults, such as hypoxia, during compromised physiological states.

Dosage and Administration Information

Piratin is administered by the oral route, using tablets, capsules, or an oral solution, but may be given intravenously when oral intake is medically compromised. The medicine can be taken with or without food, and the total daily dose is typically divided and administered in two to four sub-doses to maintain consistent levels.

The standard administration schedule is highly specific to the condition. For myoclonus, treatment often begins with a daily dose of 7.2 grams, which is then systematically increased by 4.8 grams every three to four days, up to a maximum total of 24 grams per day.

Dose adjustment is mandatory for certain populations. For older adults and patients with renal impairment, the daily amount must be individualized based on the estimated Creatinine Clearance (CLcr). Severe renal impairment (CLcr below 30 mL/min) requires a substantial reduction to approximately one-sixth of the usual dose, and treatment is contraindicated in end-stage renal disease.

When discontinuing Piratin, abrupt cessation must be strictly avoided, particularly for myoclonic patients. A gradual tapering schedule is utilized, achieved by reducing the daily amount by 1.2 grams every two days to mitigate the risk of sudden relapse or withdrawal-related seizures.

Recent Clinical Evidence

Piratin: Recent Clinical Evidence

Overview of Efficacy Studies

Research examined the drug's activity within the context of key inflammatory pathways. Studies assessed whether this activity was associated with participant-reported symptoms. Research has explored the drug's role in the context of the condition.

Key Efficacy Findings

Finding Area Research Observation
Participant Symptoms Research assessed chronic pain levels and acute flare-ups among study participants. Observed symptom reports were not uniform.
Inflammation Markers Studies observed changes in inflammation levels over time following administration. Consistency of changes over time was not reported for all participants.
Combination Therapy Studies examined outcomes following the drug’s use in combination therapy compared to standard care. Further research is needed to understand the consistency of findings.

Overview of Safety and Tolerability

Safety studies focused on observed short-term adverse events and findings from longer monitoring periods. Research reports are available detailing the side effects observed during clinical trials.

Reported Safety Profile

  • Common Side Effects: Side effects frequently reported in research included nausea, headache, and fatigue. These events were typically resolved and were reported as mild by participants.
  • Serious Adverse Events: A small percentage of participants experienced serious adverse events, including liver enzyme elevations and severe immune responses. Detailed incidence rates are available in the full study reports.
  • Specific Populations: Studies report safety profiles and known side effects in populations with pre-existing kidney conditions. Further research on long-term safety is ongoing.

Information about this treatment is for discussion with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Piratin (FAQ)

Q: How long does the effect of Piratin last after one use?

A: Official regulatory documents indicate that Piratin has an elimination half-life of approximately 4 to 5 hours in young adult men. The half-life refers to the time it takes for half of the drug to be eliminated from the body. This characteristic is related to why official dosing schedules often involve administration multiple times per day.

Q: What are the most commonly reported side effects of Piratin?

A: According to official regulatory adverse reaction tables, the most commonly reported side effects (affecting 1/100 to 1/10 patients) are nervousness, hyperkinesia (increased, often involuntary movement), and weight increased. Reactions reported less frequently include depression, drowsiness (somnolence), and weakness (asthenia).

Q: Can Piratin affect my ability to drive or operate machinery?

A: Yes, regulatory information includes a warning that Piratin may affect a person's ability to drive or operate machinery. This is due to potential side effects such as drowsiness, sleepiness, or shakiness that may occur. This is why the official label advises that caution should be exercised regarding activities that require alertness if these side effects occur.

Q: Is Piratin known to interact with birth control pills?

A: Official documents state that Piratin has a low potential for typical drug-drug interactions. This is because it is primarily eliminated unchanged by the kidneys and does not significantly inhibit the major liver enzymes (Cytochrome P450 isoforms) often involved in breaking down other medications, including hormonal contraceptives.

Q: What information exists regarding Piratin and blood pressure medication?

A: The official regulatory interaction profile does not specifically list blood pressure medications (antihypertensives) as a documented drug-drug interaction. However, potential side effects observed in trials can include an increase in blood pressure.

Q: What kind of research or clinical trials were conducted on Piratin?

A: Clinical trials and scientific studies have explored Piratin's activity in the context of various conditions. The evidence base includes research on its use for cognitive disorders, vertigo, cortical myoclonus (a movement disorder), dyslexia, and sickle cell anemia.

Q: Is Piratin generally considered a long-term or short-term treatment?

A: Official guidelines and regulatory documents describe treatment with Piratin as potentially required for the duration of the underlying condition. Long-term use is typically necessary in certain indications, and abrupt cessation is generally avoided.

Q: Are there different strengths of Piratin available?

A: Yes, official regulatory dosing information confirms that Piratin is commonly manufactured and available in specific strengths. These often include tablets of 800 mg and 1200 mg.

Q: Is Piratin a medicine that can be crushed or split?

A: Regulatory patient instructions generally describe the tablets as being swallowed whole with a drink of water. Patients are often warned not to break, crush, or chew the tablets, frequently because the active ingredient has a bitter taste.

Q: Is it required to take Piratin at a specific time of day?

A: Official instructions advise that the total daily dose is best split and administered on two or three separate occasions during the day (such as morning, midday, and evening). This divided schedule helps to maintain consistent levels of the medicine in the body.

Q: Does Piratin have a generic version available?

A: The active ingredient in Piratin is Piracetam. The commercial availability of generic versions is determined by the patent status and regulatory approval of the active ingredient, which varies significantly between countries and is tracked in official drug databases.

Q: What is the expected timeframe before Piratin starts working?

A: Studies and pharmacological properties indicate that Piratin, like many similar agents, does not typically have an immediate effect after a single dose. Therefore, an extended period of use is generally necessary before the desired therapeutic results may be noticed.

Q: Are there any serious side effects that are rare but have been documented for Piratin?

A: Official reports list certain reactions whose frequency is not known, including agitation, anxiety, confusion, and headache. In reports related to overdose, there was documentation of a case involving bloody diarrhea.

Q: Can teenagers or children take Piratin?

A: Regulatory information states that Piratin is generally not recommended for use in children. However, some official documents note that use in certain paediatric populations may be permitted under medical supervision.

Q: What is the risk classification of Piratin during pregnancy?

A: Piratin is generally not recommended during pregnancy or breastfeeding, as the drug can cross the placental barrier and is excreted in human breast milk. Regulatory documents establish a mandate for the careful assessment of expected benefits versus potential risks before Piratin is considered for use during pregnancy.

Q: Is Piratin a controlled substance?

A: The legal and regulatory status of Piratin (Piracetam) is not uniform across all global jurisdictions. In some regions, it is classified as a prescription medicine while in others, it is not formally approved for any medical use, meaning its classification can vary.

Q: What are the limitations of the current research on Piratin?

A: Scientific papers and study reports discussing Piratin often acknowledge certain limitations. These frequently include a lack of data consistency across all participants, a need for long-term safety research, or issues with generalizing results to all patient populations.

How should Piratin be stored and disposed of?

How to Store and Dispose of Piratin?

Storage of Piratin (Piracetam) must adhere strictly to the conditions specified in official regulatory labeling to maintain product stability.

Official Storage Requirements

Requirement Condition
Temperature Store at or below 25 C (room temperature).
Protection Must be kept protected from light and moisture.
Container Keep the medicine in its original packaging.
Prohibited The product must not be frozen.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Any unused or expired Piratin must be disposed of in accordance with local requirements for pharmaceutical waste. The preferred method is to utilize official drug take-back programs available in the area. Disposal into wastewater or household trash is not recommended unless following national protocols, such as mixing with an unappealing substance and sealing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Piratin found in:

A-Z Index: